Comparative Pharmacology
Head-to-head clinical analysis: LIKMEZ versus MIGLUSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIKMEZ versus MIGLUSTAT.
LIKMEZ vs MIGLUSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LIKMEZ is a combination of atorvastatin and ezetimibe. Atorvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL receptor expression. Ezetimibe inhibits intestinal cholesterol absorption by blocking the NPC1L1 transporter.
Miglustat is a glucosylceramide synthase inhibitor that reduces the synthesis of glucosylceramide, a precursor in the biosynthesis of glycosphingolipids. It acts as a competitive inhibitor of the enzyme glucosylceramide synthase, thereby decreasing the accumulation of glucosylceramide and other glycosphingolipids.
100 mg orally twice daily
100 mg orally three times daily, at regular intervals.
None Documented
None Documented
Clinical Note
moderateMiglustat + Pregabalin
"The risk or severity of heart failure can be increased when Pregabalin is combined with Miglustat."
Clinical Note
moderateEtacrynic acid + Miglustat
"The therapeutic efficacy of Miglustat can be decreased when used in combination with Etacrynic acid."
Clinical Note
moderateSunitinib + Miglustat
"Sunitinib may increase the hypoglycemic activities of Miglustat."
Clinical Note
moderateLanreotide + Miglustat
Terminal half-life: 12 hours (range 10-14 h); clinical context: allows once-daily dosing for most patients.
Terminal elimination half-life is approximately 7 hours (range 5–10 hours) in patients with normal renal function; half-life is prolonged in renal impairment, requiring dose adjustment.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Primarily renal excretion of unchanged drug. Following oral administration, approximately 80% of the dose is excreted unchanged in urine, with less than 5% recovered in feces.
Category C
Category C
Glucosylceramide Synthase Inhibitor
Glucosylceramide Synthase Inhibitor
"The therapeutic efficacy of Miglustat can be decreased when used in combination with Lanreotide."